Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3

Autor: Shiffman M. L., Suter F., Bacon B. R., Nelson D., Harley H., Sola R., Shafran S. D., Barange K., Lin A., Soman A., Zeuzem S., Crawford D., Leggett L., Roberts S., Weltman M., Greenbloom S., Menon K., Bourliere M., Brissot P., Bronowicki J. P., Doffoel M., Hezode C., Marcellin P., Tran A., Zarski J. P., Avci O., Berg T., Potthoff O., Rasenack J., Ross O., von Wagner M., Ascione A., Brunetto M., Bruno R., Bruno S., Cane E., Aguilar J., Barcena R., Diago M., Enriquez J., Garcia Samaniego J., Moreno R., Planas R., Rincon D., Testillano M., Anand B., Bilir B. Bahri, Balan V., Bank L., Barranco E., Berg C., Bernstein D., Bloom J., Bonkovsky H., Box T., Brau N., Bzowej N., Cassidy W., Clain D., Corasanti J., Davis M., DeJesus E., Delich P., Esposito S., Etzkorn K., Flora K., Fried M., Fromm H., Ghalib R., Gibas A., Godofsky E., Gompf S., Gordon S., Gordon F., Hammond G., Harrison S., Herrera J., Ho S., Howell C., Joshi S., Keeffe E., Kranz K., Kwo P., Lake Bakaar G., Larson A., Levin A., Lok A., Lucey M., Lyons M., Malet P., Malik P., Manch R., Mehra S., Mihas A., Mikolich D., Morgan T., Muir A., Nguyen R., Nunes D., Nyberg L., O'Brien C., Pappas S., Pauly M., Pedrosa M., Perkel M., Person J., Pockros P., Post A., Poulos J., Powell R., Raj V., Reed A., Reindollar R., Riley T., Rodriguez Torres M., Rubin R., Sahagun G., Schmidt W., Sepe T., Shaw Stiffel T., Sheikh A., Sherman K., Smith C., Stevens D., Sulkowski M., Toro D., Torres E., Tran T., Tsai N., Wohlman R., Wright W., Wruble L., Younossi Z., BRILLANTI, STEFANO

BACKGROUND: Patients infected with hepatitis C virus (HCV) genotype 2 or 3 have sustained virologic response rates of approximately 80% after receiving treatment with peginterferon and ribavirin for 24 weeks. We conducted a large, randomized, multina

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38d06d4d125b5f21e735f5226014a1f0
http://hdl.handle.net/11365/1070791

PROPEL: A randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients

Autor: Propel, Investigators, Thommes, J, Najera, I, Chen, Yc, Munson, Ml, Ipe, D, Vierling, J, Pockros, P, Bzowej, N, Rodriguez Torres, M, Zeuzem, S, Mm, Ma, Ferenci, P, Herring, R, Jensen, D, Wedemeyer, H, Agarwal, K, Andreone, P, Benhamou, Y, Berg, T, Bloomer, J, Bronowicki, J, Brunetto, MAURIZIA ROSSANA, Bruno, S, Calleja, Jl, Iglesias, Ma, Cheng, W, Ciancio, A, Clark, V, Crawford, D, de Lédinghen, V, Desmond, P, Diago, M, Dikopoulos, N, Freilich, B, Godofsky, E, Hassanein, T, Hézode, C, Jacobson, I, Klass, Dm, Kuo, A, Lee, Ss, Leggett, B, Macdonald, Ga, Mac Quillan, G, Marotta, P, Vila, R, Pol, S, Ramji, A, Rasenack, Jw, Ratziu, V, Roberts, S, Romero Gómez, M, Rosenberg, W, Rossaro, L, Salmeron, Fj, Sánchez Tapias, Jm, Sanyal, Aj, Scuteri, A, Sepe, T, Sheikh, A, Sherman, M, Simon, Gl, Slim, J, Smith, Jp, Solà, R, Strasser, Si, Strohecker, J, Sulkowski, M, Tran, A, Willems, B, Yoshida, E, Zachoval, R, Zarski, J. .

Mericitabine is a nucleoside analog polymerase inhibitor of hepatitis C virus (HCV). Treatment-naive HCV genotype 1 or 4 patients were randomized to double-blind treatment with oral mericitabine at a dosage of 500 mg twice-daily (BID) for 12 weeks (A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e520e34f9e35bb4e185dc082ad781d46
http://hdl.handle.net/2318/145343

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Gastric Emptying and First-Pass Metabolism of Ethanol in Elderly Subjects with and without Atrophic Gastritis.

Autor: Pedrosa, M. C., Russell, R. M., Saltzman, J. R., Golner, B. B., Dallal, G. E., Sepe, T. E., Oates, E., Egerer, G., Seitz, H. K.

Publikováno v: Scandinavian Journal of Gastroenterology; 1996, Vol. 31 Issue 7, p671-677, 7p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.